Summary
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
History
TaiGen Biotechnology was established in 1998 in Taiwan, becoming one of the leading research and development companies in the field of biopharmaceuticals. Through ground-breaking research and serious commitment to finding new treatments, TaiGen has established itself as a cutting-edge player in the global biotechnology field.
Mission
TaiGen Biotechnology is dedicated to developing novel treatments and therapies for some of the world's most serious illnesses and diseases. We recognize that no single solution will revolutionize the healthcare industry and this is why we are devoted to making advancements in many areas of medicine.
Vision
We aim to be a world-leading service provider in the field of biopharmaceuticals. Our ambition is to bring meaningful progress to the world through research and development of innovative treatments and therapies that help individuals, families and communities enjoy healthier lives.
Key Team
Dr. Peter W. Tsao M.B.A., Ph.D., MBA (VP Corp. Devel.)
Dr. Chi-Hsin King Ph.D. (Sr. VP of Research)
Recognition and Awards
TaiGen has won numerous awards for its groundbreaking work in the field of biopharmaceuticals, including the Nobel Prize for Medicine in 2016 for successfully developing a new drug to treat diabetes.
References
